CN102634515B

CN102634515B - Expression vector suitable for expressing coded sequence used for gene therapy

Info

Publication number: CN102634515B
Application number: CN 201210084816
Authority: CN
Inventors: 高垡经; 李圭铉; 李贤�; 尹成泰; 赵义哲
Original assignee: Mogam Biotechnology Research Institute
Current assignee: Mogam Biotechnology Research Institute
Priority date: 2008-02-14
Filing date: 2008-02-14
Publication date: 2013-11-06
Anticipated expiration: 2028-02-14
Also published as: CN102634515A

Abstract

The invention provides an expression vector for a gene therapy, which contains a new combination of transcriptional regulatory elements. The expression vector for the gene therapy comprises a promoter, an enhancer, an untranslated region (UTR), and a locus control region (LCR). The expression vector is capable of continuously expressing in liver tissue-specific genes, thus the expression vector can be effectively used for treating thrombosis, hemophilia, liver cancer, and the like.

Description

Be suitable for expressing the expression vector for the encoding sequence of gene therapy

The application is that application number is dividing an application of 200880126705.0 Chinese patent application, and original application is the China national phase application of International Application Serial No. PCT/KnR2008/000870.

Technical field

The present invention relates to the expression vector for gene therapy, relate more particularly to comprise the expression vector that is used for gene therapy of the new combination of transcriptional regulatory element (cis-regulating element or transacting element), it comprises promotor, enhanser, intron, non-translational region (UTR) and region (locus control region, LCR), described carrier can support target gene in liver with high-level continuous expression.

Background technology

The function of liver comprises that blood stores, sugar is changed and the secretion cytokine profiles, and expresses the gene that affects numerous disease (as heredity, cardiovascular, metabolism, blood and Cancerous disease).The target of multiple liver specificity disease (as infectious hepatitis) as gene therapy is studied.

Liver cell has the very long life-span after formation, have the acceptor of most of virogene translocators and directly be connected with blood flow, makes it be easy to contact medicine, so liver is considered to important candidate's organ of gene therapy.

Hemophilia is a kind of by being positioned at Factor IX (FVIII, f8) on X chromosome or the caused degeneration hemorrhagic disease of defective of factors IX (FIX, f9) gene, is divided into hemophilia A (FVIII defective) or B (FIX defective) according to the gene of sudden change or disappearance.To being used for the treatment of the medicine of hemophilia A or B, to only have as FVIII or FIX during with the 1-5% (being respectively 100-200ng/ml and 500ng/ml) of its normal blood concentration or higher level continuous expression, result for the treatment of is only expected.

In nearest Study of Gene Therapy for Hemophilia B, what reported is, to introduce with the adeno-associated virus (AAV) of people FIX (hFIX) gene causes hFIX albumen with up to 1 in the hemophilia B mouse model, 500-1, horizontal expression (the Snyder of 800ng/ml, R.O., Nat.Med., 5:64-70 (1999); Manno, C.S., Nat.Med., 12:342-347 (2006)), and in the dog model of hemophilia B with the horizontal expression hFIX albumen (Arruda, V.R., Blood, 105:3458-3464 (2005)) up to 730ng/ml.Yet, when with this when the carrier clinical application of high efficient expression is in people patient in animal model, the haemoconcentration of FIX is only 185ng/ml or lower, this is lower than the threshold value (500ng/ml) of effective clinical treatment, an other difficult problem be the hFIX expression level in people experimenter be not continue but instantaneous (Kay, M.A., Nat.Genet., 24:257-261 (2000); Manno, C.S., Nat.Med., 12:342-347 (2006)).Found in the treatment model of hemophilia A and above-mentioned similar trend.

Clinical test results for genetic diseases (as hemophilia) treatment shows, the most important condition is that exploitation can remain on the high-efficiency tissue specific expression vector that continues the high level expression therapeutic gene in particular organization's (as hepatic tissue).In addition, escape for body fluid and the cellullar immunologic response of carrier and induce immunological tolerance to expressed albumen to be considered to the key factor of successful gene therapy.For example, for the expression level of normal FVIII or FIX being brought up to the threshold value that is effective to successful clinical treatment, what also must consider is, the injection high dosage with the virus of FVIII or FIX gene and suppress immunne response in body.Yet for this method is succeeded, at first to improve the efficient of genetic expression by improving expression vector.

The lipoprotein that only produces in liver (a) is another the important target for the exploitation of liver tissue-specific expression vector.Lipoprotein (a) is (Fless that forms by lipophorin (a) (a kind of glycoprotein) and apo B-100 (the main protein component of low-density lipoprotein (LDL)) combination, G.M., J.Biol.Chem., 261:8712-8717 (1986)).Lipophorin (a) is responsible for the interior transhipment of body of cholesterol, the raising of having reported lipoprotein in blood plasma (a) concentration is arteriosclerosis and the cardiopathic principal risk factor (Armstrong, V. W. etc., Arteriosclerosis, 62:249-257 (1986); Assmann, G., Am.J.Cardiol., 77:1179-1184 (1996)).Lipophorin (a) contains the two class kringle structural domains similar with V to proplasmin kringle IV, and the proteolytic enzyme spline structure territory of non-activity.Well-known is that the protein with kringle structure can suppress neovascularization and transfer (Folkman J., N Eng J Med, the 285:1182-1186 (1971) of tumour; Falkman J, Klagsbrun M., Science, 235:442-447 (1987); Scapaticci FA., J Clin Oncol., 20:3906-3927 (2002)).Recently, the inventor and other investigators find, the kringle structural domain of lipophorin (a) has anticancer due to its significant anti-angiogenic activity and antimetastatic activity (Sculter V etc., ArteriosclerThromb Vasc Biol, 21:433-438 (2001); Trieu UN and Uckun FM., Biochem Biophys Res Commun., 257:714-718 (1999); Kim JS etc., J.BiolChem., 278:29000-29008 (2003); Yu HK etc., Cancer Res., 64:7092-7098 (2004); Kim JS etc., Biochem Biophys Res Commun., 313:534-540 (2004); Lee K etc., Hepatology, 43:1063-1073 (2006)).

In anti-metastasis and anticancer therapy, be recognized that, the therapeutic modality of selectively acting on ill site can be more effective.Therefore, exploitation be used for anticancer therapy (for example be used for liver cancer or shift the effective gene treatment of liver tumor) can tissue specificity to continue to carry out the carrier of genetic expression extremely important on ground.

As mentioned above, it is the key of effective gene treatment that the tissue-specific gene that continues is expressed, and this need to develop new improvement expression vector.This can realize by the transcriptional regulatory element (cis-regulating element or transacting element) that improves this expression vector.

The example of transcriptional regulatory element commonly used comprises promotor, enhanser, intron, non-coding region, region etc.

that use in the expression vector that this liver tissue-specific is expressed is phosphoric acid enol pyruvic acid carboxylase (PEPCK, be the gluconeogenesis enzyme) (Yang, Y.W., J. etc., Gene Med., 5 (5): 417-424 (2003)), alpha1-antitrypsin, albumin, FVII, organic anion transhipment peptide C (OATP-C), hepatitis B virus core protein (Kramer, M.G., Deng, Mol.Ther., 375-385 (2003)) and thyroid binding globulin (Wang 7 (3):, L., Deng, Proc.Natl.Acad.Sci., 96:3906-3910 (1999)) promotor, and albumin (Kang, Y., Deng, Blood, 106 (5): 1552-1558 (2005)), Phenylalanine hydroxylase (PAH) and α 1-microglobulin/urine press down pancreozymin (bikunin) precursor (AMBP) (Wang, L., etc., Mol.Ther., 1 (2): enhanser 154-158 (2000)).

Due to liver in HNF-4 (Hepatic nuclear factor-4) combination of being rich in, the transcription activating level of FVII promotor (size is about 500bp) in liver is in its hetero-organization 10 times or higher.What reported is, most of transcription factors mainly be combined on the 300bp fragment of FVII promotor 3 ' end (Greenberg, D., etc., Proc.Natl.Acad.Sci., 92:12347-12351 (1995)).When the 315bp fragment of brachymemma FVII promotor (size is 501bp) 5 ' end, the liver specificity of promotor is active improves approximately 30%, but the about 20-30% (Pollak of activity decreased when brachymemma 210bp fragment, W.S., Deng, J.Biol.Chem., 271 (3): 1738-1747 (1996)).

Because the HNF-1 α that is rich in liver is combined, the transcription activating level of promotor (size is about 900bp) in liver of organic anion transhipment peptide C (OATP-C) is in its hetero-organization 3 times or higher.What reported is, most of transcription factors be combined on the 440bp fragment of promotor 3 ' end (Jung, D., etc., J.Biol.Chem., 276:37206-37214 (2001)).

Can strengthen by the effect of enhanser the activity of promotor.Phenylalanine hydroxylase (PAH) enhanser (size is about 230bp, and has the HNF-1 binding site) is positioned at PAH gene 5 ' end upstream-3.5kb.What reported is, due to the binding site of the HNF-1 that exists liver to be rich in, the PAH enhanser make the activity of the promotor of its combination rise to 4 times or higher (Lei, X.D., etc., Proc.Natl.Acad.Sci., 95:1500-1504 (1998)).

AMBP (α 1-microglobulin/urine press down pancreozymin precursor) enhanser size is about 400bp, its from AMBP gene 5 ' end-2945bp extends to-2539bp.It mainly comprises HNF-1,2,3 and 4 binding site, its main active region corresponding to its fragment of-2802 to-2659bp (Route, P., etc., Biochem.J., 334:577-584 (1998)).What reported is that the AMBP enhanser generally makes promoter activity rise to twice or three times.

The non-translational region (UTR) that is positioned at gene 5 ' and 3 ' end is responsible for Stability Analysis of Structures (Holcik, M., Liebhaber S.A., Proc Natl Acad Sci USA., the 94:2410-2414 (1997) of gene mRNA; Chkheidze, A.N., etc., Mol Cell Biol., 19:4572-4581 (1999)).What reported is, the polyadenylation signal sequence in 3 ' UTR also obviously help mRNA Stability Analysis of Structures (Kolev, N.G., etc., Genes Dev., 19:2583-2592 (2005)).

Eukaryotic gene comprises exon (being translated into protein) and intron (non-translated sequence between exon).Remove these introns by montage, make by DNA and at first transcribe the mRNA that the mRNA precursor that obtains changes maturation into.These introns comprise with the donor splicing site of GT (U) beginning and the acceptor splicing site that ends up with AG.In addition, appear at introne 3 ' what hold is poly pyrimidine fragment, splicing factor, snRNP conjugate branch sequence, three guanine tumor-necrosis factor glycoproteinss (3 heavy G motif) etc., their (Pagani that plays a crucial role in the process that forms spliceosome (mixture of RNA and intron splicing enzyme), F., Deng, Nat.Rev.Genet., 5:389-396 (2004)).

When with promotor and enhanser combination, intron can be used as the transcriptional regulatory element of expressing for continuing high efficiency gene.Intron by be combined with transcription factor participate in improving gene expression efficiency and transcribe efficient (Liu, K., etc., Proc.Natl.Acad.Sci., 92:7724-7728 (1995); LeBlanc, S.E., etc., J.Biol.Chem., (2005)), also participate in improving the protein translation efficient (Moore, M.J., Cell, 108:431-434 (2002)) after transcribing.What reported is, the introne 1 of hFIX cause the hFIX protein expression increase (Kurachi, S., etc., J.Biol.Chem., 270:5276-5281 (1995)).

Anticoagulant protein (as antithrombin and proplasmin) and thrombin (as thrombogen) are all expressed in liver.Be the thrombosis of defective type or haemophiliac's gene intron by analyzing these albumen, multiple missense mutation and/or nonsense mutation have been found, this intron of pointing out these protein is to (the Jochmans that plays a crucial role of the genetic expression in liver, K., Deng, Blood, 84:3742-3748 (1994)).

Found to have region (LCR) at least 36 kinds of Mammalss (comprising people, rat, rabbit, goat etc.).LCR is the nucleotide sequence that contains DNase I sensitive area (it has tissue specificity to transcription factor).The function of human beta-globin LCR is well-known (Harju S. etc., Exp.Biol.Med.227:683-700 (2002)).

Liver cell control region (hepatocyte control region, HCR) is well-known because of the ability that it strengthens liver specificity genetic expression, and this district is found in the downstream of apo E (ApoE) gene.HCR has the DNase I sensitizing range of being combined with the liver specificity transcription factor.The LCR that HCR expresses as the liver specificity of ApoE gene.ApoE HCR have with the multiple factor (as HNF3 α, HNF4, GATA-1, C/EBP, TF-LF2 and Alu family) in conjunction with the time site that is activated.In these sites, the HNF3 α binding site that shows DNase I supersensitivity has the TGTTTGC motif, DNase I can cut connection between first G and second T (Dang Q., etc., J.Biol.Chem.270:22577-22585 (1995)).In fact, reported introduce in the expression vector ApoE HCR cause in animal model hFIX to express improving (Miao C.H., etc., Mol.Ther.1:522-532 (2000)).

Reported albumen (the Dang Q. with sequence similar to alpha-fetoprotein, albumin etc. in the HCR (comprising the TGTTTGC motif) of people ApoE gene, people's apolipoprotein A-1, apolipoprotein B, Transferrins,iron complexes, alpha-fetoprotein, alpha1-antitrypsin etc. and mouse, Deng., J.Biol.Chem.270:22577-22585 (1995)).

Summary of the invention

Therefore, an object of the present invention is to provide the polynucleotide that can be used as transcriptional regulatory element, described transcriptional regulatory element is used for high-level continuous expression liver tissue-specific gene.

Another object of the present invention is to provide for the expression vector with high-level continuous expression liver tissue-specific gene.

The polynucleotide of the nucleotide sequence with SEQ ID NO:42 are provided according to an aspect of the present invention.

According to a further aspect in the invention, polynucleotide are provided, it comprises: have the polynucleotide of nucleotide sequence of SEQ ID NO:42 and at least one polynucleotide that Nucleotide effectively is connected more than SEQ ID NO:42, the latter is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:44 and 45.

According to a further aspect in the invention, provide polynucleotide, it is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:46 to 57.

According to a further aspect in the invention, provide polynucleotide, it is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:58 to 61.

According to a further aspect in the invention, provide expression vector, it comprises transcriptional regulatory element and effectively is connected and is subjected to the encoding sequence of its control with described transcriptional regulatory element, and wherein said transcriptional regulatory element comprises:

1) have the polynucleotide of the nucleotide sequence of SEQ ID NO:42;

2) have the polynucleotide of nucleotide sequence of SEQ ID NO:42 and at least one polynucleotide that Nucleotide effectively is connected more than SEQ ID NO:42, the latter is selected from the polynucleotide of the nucleotide sequence with SEQ IDNO:44 and 45;

3) have the polynucleotide of nucleotide sequence of SEQ ID NO:42 and at least one polynucleotide that Nucleotide effectively is connected more than SEQ ID NO:42, the latter is selected from the polynucleotide of the nucleotide sequence with SEQ IDNO:46 to 57;

4) have the polynucleotide of nucleotide sequence of SEQ ID NO:42 and at least one polynucleotide that Nucleotide effectively is connected more than SEQ ID NO:42, the latter is selected from the polynucleotide of the nucleotide sequence with SEQ IDNO:58 to 61;

5) have the polynucleotide of the nucleotide sequence of SEQ ID NO:42; Be selected from least one polynucleotide of the polynucleotide of the nucleotide sequence with SEQ IDNO:44 and 45; And at least one polynucleotide that is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:46 to 57; Described polynucleotide effectively connect each other;

6) have the polynucleotide of the nucleotide sequence of SEQ ID NO:42; Be selected from least one polynucleotide of the polynucleotide of the nucleotide sequence with SEQ IDNO:44 and 45; And at least one polynucleotide that is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:58 to 61; Described polynucleotide effectively connect each other;

7) have the polynucleotide of the nucleotide sequence of SEQ ID NO:42; Be selected from least one polynucleotide of the polynucleotide of the nucleotide sequence with SEQ IDNO:46 to 57; And at least one polynucleotide that is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:58 to 61; Described polynucleotide effectively connect each other; Perhaps

8) have the polynucleotide of the nucleotide sequence of SEQ ID NO:42; Be selected from least one polynucleotide of the polynucleotide of the nucleotide sequence with SEQ IDNO:44 and 45; Be selected from least one polynucleotide of the polynucleotide of the nucleotide sequence with SEQ ID NO:46 to 57; And at least one polynucleotide that is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:58 to 61; Described polynucleotide effectively connect each other.

According to a further aspect in the invention, expression vector is provided, it comprises transcriptional regulatory element and effectively is connected and is subjected to the encoding sequence of its control with described transcriptional regulatory element, described transcriptional regulatory element comprises promotor and the polynucleotide that effectively are connected with described promotor, and described polynucleotide are selected from: at least one polynucleotide that is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:46 to 57; Be selected from least one polynucleotide of the polynucleotide of the nucleotide sequence with SEQ ID NO:58 to 61; And have at least one polynucleotide of SEQ ID NO:46 Nucleotide more than 57 nucleotide sequences with being selected from of being selected from that at least one polynucleotide with SEQ ID NO:58 Nucleotide more than 61 nucleotide sequences effectively are connected.

Description of drawings

By to following description of the present invention in conjunction with following accompanying drawing, above-mentioned purpose and the feature with other of the present invention will become apparent, described accompanying drawing shows respectively:

Figure 1A: comprise the FVII promotor pCR-FVII Pro plasmid, comprise the pCR-OATP-C Pro plasmid of organic anion transport peptide C (OATP-C) promotor and comprise the schematic diagram of the pCR-AAT Enh/Pro plasmid of alpha antitrypsin (AAT) promotor/enhanser;

Figure 1B: the schematic diagram of mRLuc luciferase expression carrier pmRL-FVII Pro, pmRL-FVII Δ Pro and pmRL-OATP-C Pro, it contains respectively FVII (FVII Δ) promotor and the OATP-C promotor of FVII promotor, brachymemma;

Fig. 2 A: histogram, it shows that FVII promotor and OATP-C promotor are that (HUVEC), human hepatocellular carcinoma cell line (Huh-7), human kidney cells are the expression efficiency in (HEK293), human lung adenocarcinoma epithelial cell line (A549) and Human cervical cancer cell lines (HeLa) in Human umbilical vein endothelial cells;

Fig. 2 B: contain the schematic diagram of the luciferase expression box of FVII promotor and FVII Δ promotor, and the histogram of more described promoter expression efficient;

Fig. 2 C: histogram, it shows the expression efficiency of FVII Δ promotor, OATP-C promotor, hepatitis B virus core protein (HBcP) promotor, endothelium glycoprotein (Endoglin) promotor, cell adhesion molecule (ICAM2) promotor and tyrosine kinase receptor (Tie2) promotor by the mode with the comparison of CMV promotor;

The schematic diagram of Fig. 3 A:pCR-PAH enh and pCR-AMBP enh plasmid, it contains respectively Phenylalanine hydroxylase (PAH) enhanser and α 1-microglobulin/urine presses down pancreozymin precursor (AMBP) enhanser;

The schematic diagram of Fig. 3 B:pmRL-PF, pmRL-AF, pmRL-PAF, pmRL-PO, pmRL-AO and pmRL-PAO expression vector, it is by to the pmRL-FVII Δ Pro expression vector that contains FVII Δ promotor or contain and insert at least a structure that is selected from PAH enhanser and AMBP enhanser in the pmRL-OATP-CPro expression vector of OATP-C promotor and form;

Fig. 4 A: histogram, it shows different according to PAH enhanser and AMBP enhanser and FVII Δ, OATP-C, Tie-2 and ICAM2 promotor array mode, the external luciferase expression level in A549, HeLa and Huh-7;

Fig. 4 B: histogram, it shows when the combination of AMBP enhanser and FVII promotor luciferase expression efficient in HEK293, A549, HeLa, Huh-7, Bel7402 (Hep3B) and HUVEC by the mode with the comparison of CMV promotor;

Fig. 4 C: histogram, it is presented at after mixture with jetPEI in every kind of expression vector and polymine (PEI) or body is injected into mouse tail vein, with the luciferase expression efficient of expression vector in hepatic tissue of expression cassette, described expression cassette contains the promotor that shows in PAH enhanser, AMBP enhanser, cmv enhancer and SV40 enhanser and Fig. 4 A;

Fig. 5: the schematic diagram (SD, the donor splicing site that do not contain the hFIX expression plasmid (FIX) of UTR and contain the hFIX expression plasmid (FIXUTR) ((a)) of UTR and contain the FIXUTR plasmid ((b), (c) and (d)) of multiple intron; SA, acceptor splicing site; (G) 3, three guanine motifs; BS, branched sequence);

Fig. 6 A:ELISA result, it shows the hFIX protein expression level in the plasma sample obtain from mouse, described mouse by tail vein injection with the expression vector of CMV-hFIXUTR-Syn1int, CMV-hFIXUTR-Syn2int, CMV-hFIX and CMV-hFIXUTR expression cassette;

Fig. 6 B:ELISA result, it is presented at weekly the hFIX protein expression level from the plasma sample that the immunodeficiency type mouse obtains, and has injected in described mouse with 1 * 10 of the recombinant adeno-associated virus of CMV-hFIXUTR-Synlint expression cassette ⁹Individual infectious particles (IP);

Fig. 7 A: the schematic diagram of luciferase expression box, described expression cassette contains intron in the RLuc luciferase genes that controlled by the TK promotor;

Fig. 7 B: histogram, it is presented at uses with Hep3B, the HEK293 of the expression vector transfection of expression cassette (it contains multiple intron in Fig. 7 A) and the luciferase expression level in the A549 cell;

Fig. 8 A: reverse transcription PCR (RT-PCR) result, it is presented at the mrna expression level of the middle RLuc of total RNA (extracting) and beta-actin from the A549 cell with the transfection of Fig. 7 B expression vector;

Fig. 8 B: histogram, its demonstration is carried out normalized RLuc mrna expression level with beta-actin to the RLuc and the beta-actin mRNA band intensity that obtain in Fig. 8 A;

Fig. 9 A:ELISA result, it shows the hFIX protein expression level in the plasma sample obtain from mouse, described mouse by tail vein injection with CMV-hFIXUTR-Syn1AT, CMV-hFIXUTR-Syn2AT, CMV-hFIXUTR-NA, CMV-hFIXUTR-Δ NAL, CMV-hFIXUTR-Δ NAS expression cassette and in contrast with CMV-hFIXUTR-0.3kbFIXint (CMV-hFIXm2) the expression cassette expression vector of (containing 0.3kb FIX intron);

Fig. 9 B:Western engram analysis result, it is presented at the hFIX protein expression level of using with in the HEK293T of the expression vector transfection of CMV-hFIX, CMV-hFIXUTR and CMV-hFIXUTR-Δ NAL expression cassette;

Figure 10: schematic diagram, it shows in the 5 ' distolateral pterion of alpha-fetoprotein, AAT and albumin gene, with the distribution of the same or analogous motif of TGTTTGC motif of finding in the LCR of Apo E gene;

The schematic diagram of Figure 11 A:pCR-HCR and pCR-HCRm plasmid (containing respectively HCR (being known as the liver cell control region of Apo E gene) and HCRm (being known as the minimum HCR structure of brachymemma TGTTTGC motif)) and pCR-AAT7800lcr/pCR-AAT108lcr, pCR-AFP3800lcr and pCR-E6lcr plasmid (containing respectively alpha-fetoprotein, AAT and albuminous TGTTTGC motif);

The schematic diagram of Figure 11 B:pBS-HCRm-AATenh/pro (HmA) plasmid (forming by insert HCRm, AAT enhanser and AAT promotor structure in the pBluescriptII carrier) and pBS-HCR-AATpro (HA) plasmid (build by insertion HCR and AAT promotor in pBluescript II carrier and form);

Figure 12 A: the schematic diagram of expression cassette, it obtains by introduce multiple LCR (HCR, HCRm, AFP3800, AAT7800, AAT108 and E6) in the hFIX expression cassette that contains PAH enhanser, FVII Δ promotor and intron Syn1PLA;

Figure 12 B:ELISA result, it shows hFIX protein expression level in the plasma sample obtain from mouse, described mouse by tail vein injection with expression vector and the CMV-hFIXUTR-Syn1PLA expression vector of Figure 12 A expression cassette;

Figure 13 A: schematic diagram, its demonstration contain the expression cassette of combination, NAL intron and the AAT108LCR of the combination of PAH enhanser and FVII Δ promotor (PF) or PAH enhanser, AMBP enhanser and FVII Δ promotor (PAF); HmA (HCRm-AATenh/pro)-hFIXUTR-Δ NAL expression cassette; And HA (HCR-AATpro)-hFIXUTR-1.4kbFIXint expression cassette;

Figure 13 B:ELISA result, it shows hFIX protein expression level in the plasma sample obtain from mouse, described mouse by tail vein injection with expression vector and the CMV-hFIXUTR-Δ NAL expression vector of Figure 13 A expression cassette;

Figure 13 C and 13D: use the plasma sample that obtains in Figure 13 B, by activated partial thromboplastin time (activated partial thromboplastin time, APTT) measured clotting time and the activity of method;

Figure 14 A and 14B: show respectively the result of hFIX protein expression level (measuring by ELISA) in the plasma sample that obtains from the hemophilia B mouse and blood coagulation activity (measuring by the APTT method), described mouse has been used with AAT 108-PF-hFIXUTR-Δ NAL and AAT108-PAF-hFIXUTR-Δ NAL expression cassette and in contrast with 2 * 10 of the recombinant adeno-associated virus of common HA-hFIXUTR-1.4kbFIXint and CMV-hFIXUTR-1.4kbFIXint expression cassette by portal vein ⁹Individual infective granule (IP);

Figure 15 A: the schematic diagram of expression vector, it forms by introduce multiple LCR (HCR, HCRm, AFP3800, AAT7800, AAT108 and E6) structure in PF-LK68-Δ NAL-UTR expression cassette;

The schematic diagram of Figure 15 B:AAT108-PF/PAF-LK68 expression vector, AAT108-PF/PAF-LK68-UTR expression vector and AAT108-PF/PAF-LK68-Δ NAL-UTR expression vector;

Figure 16 A: show the ELISA result of LK68 protein expression level in the plasma sample obtain from mouse, described mouse by tail vein injection with the expression vector of the PF-LK68-Δ NAL-UTR expression cassette of introducing multiple LCR (HCR, HCRm, AFP3800, AAT7800, AAT 108 and E6);

Figure 16 B: show the ELISA result of LK68 protein expression level in the plasma sample obtain from mouse, described mouse by tail vein injection with the expression vector of the AAT108-PF/PAF-LK68 expression cassette of introducing UTR or UTR and intron Δ NAL;

Figure 17 A: the Western engram analysis result of LK68 protein expression level in HEK293 cell and substratum thereof, described cell use the replication-defective adenoviral with CMV-LK68 and CMV-LK68-Δ NAL-UTR expression cassette to carry out transfection with different infection multiplicity ratios (MOI); And

Figure 17 B: the histogram of the band intensity that obtains from the Western engram analysis result of Figure 17 A, to show that UTR and intron are on the impact of genetic expression.

Embodiment

Unless otherwise defined, otherwise scientific and technical terminology used herein has the common same meaning of understanding of those skilled in the art.In addition, the All Files of mentioning is herein all incorporated this paper by reference into its integral body.

The carrier that term used herein " expression vector " is intended to be interpreted as aggregate (expression cassette or construct) or comprises this aggregate, described aggregate comprises encoding sequence, promotor, and randomly comprises the one or more transcriptional regulatory elements that effectively are connected with encoding sequence.

Term used herein " encoding sequence " refers to the DNA sequence dna of coded amino acid or functional r NA.

Term used herein " transcriptional regulatory element (cis regulatory elements or cis-acting elements) " refers to be positioned at the nucleotide sequence in encoding sequence upstream, inside or downstream, it controls rna transcription, and the processing of institute's transcribe rna, stability and translation subsequently.Transcriptional regulatory element comprises promotor, enhanser, intron, 5 ' and 3 ' non-translational region (UTR) and region (LCR).

Term used herein " promotor " and " enhanser " are encoding sequence to be transcribed into the required DNA sequence dna of RNA represent fragment.Usually, promotor refers to that the DNA section of being combined with polysaccharase and transcription factor, enhanser refer to the DNA section of being combined with the polysaccharase activation domain.

Term used herein " non-translational region (UTR) " is to be positioned at encoding sequence 3 ' end and the 5 ' sequence of holding, and it comprises as the polyadenous purine signal of transcription termination region etc.

Term used herein " intron " is the untranslated nucleotide sequence that is positioned between exon (being translated into protein after transcribing).After removing intron by montage, the mRNA precursor of transcribing changes ripe mRNA into.Term used herein " intron " also is intended to be interpreted as donor splicing site, acceptor splicing site, three guanine tumor-necrosis factor glycoproteinss (triple G motif) and/or branched sequence.

Term used herein " region (LCR) " refers to have the nucleotide sequence in DNase I susceptibility site.Tissue-specific transcription factor is incorporated into LCR.

Term used herein " effectively connects " and refers to one or more nucleotide sequences and the coupling of single core acid fragment, to affect the function of described individual chip.For example, promotor effectively is connected to strengthen the expression of described encoding sequence with encoding sequence.

Describe the present invention hereinafter.

As previously mentioned, to the efficient gene therapy, should be with the specific expressed target gene of continuous fashion in particular organization or cell, so that target gene substitutes Disease-causing gene.For realizing that tissue specificity continues genetic expression, need to comprise the expression vector of improved transcriptional regulatory element.

Therefore, the invention provides FVII (FVII Δ) promotor of brachymemma, it has the nucleotide sequence as shown in SEQ IDNO:42, and described nucleotide sequence is clipped 5 ' of 504bp FVII promotor and held upstream 207bp fragment to produce by lack XhoI (5 ' end) and BamHI (3 ' end) restriction site from the nucleotide sequence of SEQ ID NO:41.Following embodiment shows that activity that described FVII Δ promotor has is not 2.5 times of brachymemma FVII promotor or higher.

FVII Δ promotor can with suitable enhanser (for example be selected from the PAH enhanser with nucleotide sequence in SEQ IDNO:44 as previously mentioned and have at least a in the AMBP enhanser of nucleotide sequence in SEQ ID NO:45 as previously mentioned) combination.

The present invention also provides intron, and it is selected from the polynucleotide with nucleotide sequence in SEQ ID NO:46 to 57 as previously mentioned.

SEQ ID NO:46,47 and 48 intron are produced by the introne 1 of brachymemma people antithrombin, proplasmin and thrombogen respectively.SEQ ID NO:49,50 and 51 intron are the introns that synthesizes, it comprises respectively SEQ ID NO:46,47 and 48 nucleotide sequence, and total splice acceptor sequence, derives from the three guanine tumor-necrosis factor glycoproteinss (triple G motif) of people's α-globin intron 2, the branched sequence of Human Plasminogen and total splice acceptor sequence.SEQ ID NO:52,53 and 54 intron are the introns that synthesizes, and it lacks respectively triple G motifs and the branched sequence of SEQ ID NO:49,50 and 51 nucleotide sequence.The intron of SEQ ID NO:55 is synthetic intron, and it comprises total length introne 1, donor splicing site sequence and the total splice acceptor sequence of antithrombin; SEQ ID NO:56 and 57 intron are the introns that synthesizes, and it is produced by the nucleotide sequence of brachymemma SEQ ID NO:55.In above-mentioned intron, the more preferably intron of SEQ ID NO:57.

The present invention also provides region (LCR), and it is selected from the polynucleotide with nucleotide sequence as shown in SEQ ID NO:58 to 61.

SEQ ID NO:58,59,60 and 61 LCR lay respectively at people's alpha1-antitrypsin upstream region of gene-108bp and-7.8kb place, human a-fetoprotein upstream-3.8kb place and human albumin upstream region of gene-6kb place, the wherein LCR of preferred SEQ ID NO:58.

Basic identical and intimate polynucleotide also within the scope of the invention with the sequence of mentioning in the present invention.Term " basic identical and intimate polynucleotide " refers to that a certain polynucleotide and another polynucleotide have 70% at least, preferred 80%, more preferably 90%, most preferably 95% identity, and wherein said identity is determined by computerized algorithm or software.

The present invention also provides expression vector, and it comprises transcriptional regulatory element and effectively is connected and is subjected to the encoding sequence of its control with described transcriptional regulatory element, and wherein said transcriptional regulatory element comprises:

1) have the polynucleotide of the nucleotide sequence of SEQ ID NO:42;

8) have the polynucleotide of the nucleotide sequence of SEQ ID NO:42; Be selected from least one polynucleotide of the polynucleotide of the nucleotide sequence with SEQ IDNO:44 and 45; Be selected from least one polynucleotide of the polynucleotide of the nucleotide sequence with SEQ ID NO:46 to 57;

And at least one polynucleotide that is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:58 to 61; Described polynucleotide effectively connect each other.

The present invention also provides expression vector, it comprises transcriptional regulatory element and effectively is connected and is subjected to the encoding sequence of its regulation and control with described transcriptional regulatory element, described transcriptional regulatory element comprises promotor and the polynucleotide that effectively are connected with described promotor, and described polynucleotide are selected from: at least one polynucleotide that is selected from the polynucleotide of the nucleotide sequence with SEQ IDNO:46 to 57; Be selected from least one polynucleotide of the polynucleotide of the nucleotide sequence with SEQ ID NO:58 to 61; And have at least one polynucleotide of SEQ ID NO:46 Nucleotide more than 57 nucleotide sequences with being selected from of being selected from that at least one polynucleotide with SEQ ID NO:58 Nucleotide more than 61 nucleotide sequences effectively are connected.

Preferably, expression vector also can be included in the polynucleotide that encoding sequence 5 ' and 3 ' is held the nucleotide sequence with SEQ ID NO:62 and 63.SEQ ID NO:62 and 63 nucleotide sequence can be from 5 ' and 3 ' UTR of FIX gene.

The nucleotide sequence of the optional own coding liver-specific protein of encoding sequence matter, described protein includes but not limited to albumin, alpha-fetoprotein, alpha-glucosidase, alpha1-antitrypsin, antithrombin, lipoprotein, ceruloplasmin, FVII, FVIII, FIX, erythropoietin, Fibrinogen, glucocerebrosidase, haptoglobin, IGF-1, Regular Insulin, proplasmin, thrombogen and Transferrins,iron complexes.

Encoding sequence is connected and controllably is connected with promotor, enhanser, intron, UTR and LCR.

As mentioned above, the appropriate combination of transcriptional regulatory element of the present invention can realize the liver tissue-specific expression of target encoding sequence, and helps mRNA stable, therefore the expression of encoding sequence is enhanced.Comprise the expression cassette of various combinations of above-mentioned transcriptional regulatory element or carrier can make the target encoding sequence in hepatic tissue with high-level continuous expression, therefore can be widely used in the treatment of thrombosis, hemophilia, liver cancer etc.

Following embodiment is intended to illustrate the present invention and does not limit its scope.

Embodiment 1: liver tissue-specific is expressed separating and activation analysis of promotor and enhanser

＜step 1〉liver tissue-specific expresses separation and the activation analysis of promotor

Use DNeasy Tissue Kit (Qiagen) to extract genomic dna from the cell lysate of human liver cell system (Chang cell).In order to separate the FVII promotor, use primer sets and the archaeal dna polymerase (Ex-Taq, Takara) of genomic dna as template, SEQ ID NO:1 and 2 to carry out PCR, with the DNA fragmentation of the nucleotide sequence that obtains to have SEQ ID NO:41.Particularly, PCR carries out according to following condition: at first 94 ℃ of sex change 5 minutes; 30 seconds, 56 ℃ annealing of 94 ℃ of sex change 30 seconds and 72 ℃ of 30 circulations of extending 1 minute; 72 ℃ of final extensions 3 minutes.The PCR product is carried out purifying by gel extraction, and be inserted in the pCR2.1-TOPO plasmid vector.FVII promotor with nucleotide sequence of SEQ ID NO:41 is identified by restriction map and sequential analysis.The plasmid called after " pCR-FVII pro " that contains the FVII promotor.In addition, carrying out as mentioned before PCR (but outside the primer sets (SEQ ID NO:5 and 6) of the primer sets (SEQ ID NO:3 and 4) of use OATP-C promotor and AAT promotor, is inserted into the PCR product in the pCR2.1-TOPO plasmid vector.OATP-C promotor (nucleotide sequence with SEQ ID NO:43) and AAT promotor are identified by restriction map and sequential analysis.The plasmid difference called after " pCR-OATP-C pro " and " pCR-AAT enh/pro " that contains OATP-C promotor and AAT promotor.The schematic diagram of pCR-FVII pro, pCR-OATP-C pro and pCR-AATenh/pro is shown in Figure 1A.

SV40 poly in late period (A) in the phRL-null carrier (Promega) of expression Rluc is replaced to the poly (A) of human growth hormone, and from wherein removing T7 promotor and intron, to build the pmRL-null carrier.Described pmRL-null carrier is digested and processes with shrimp alkaline phosphotase with Restriction Enzyme BglII.

With BamHI digestion pCR-FVII pro and pCR-OATP-C pro plasmid.Resulting DNA fragmentation carries out purifying by gel extraction, and is inserted in the pmRL-null carrier for preparing in advance.Identify required DNA fragmentation in each plasmid vector by restriction map.Described plasmid vector called after " pmRL-FVII Pro " and " pmRL-OATP-C Pro ".

Simultaneously, cut out in pmRL-FVII Pro the approximately fragment of 200bp of FVII promotor 5 ' end with the EcoRI Restriction Enzyme, then by connecting to build the pmRL-FVII Δ Pro plasmid with brachymemma FVII (FVII Δ) promotor (nucleotide sequence with SEQ ID NO:42).

The schematic diagram of pmRL-FVII Pro, pmRL-OATP-C Pro and pmRL-FVII Δ Pro is shown in Figure 1B.

Be the luciferase expression level of pmRL-FVII Pro, pmRL-FVII Δ Pro and pmRL-OATP-C Pro of measuring in (Huh-7, HepG2, Hep3B), kidney cell line (HEK293), lung cancer cell line (A549) and cervical cancer tumer line (HeLa) at human liver cell.Particularly, with polymine (PEI) reagent (Polyplus, Illkirch, France) culturing cell in each hole of six orifice plates, to reach 70 to 80% converge.Cultured cells is carried out transfection with each and pcDNA-lacZ plasmid 1 μ g in pmRL-FVII Pro, the pmRL-FVII Δ Pro of 2 μ g and pmRL-OATP-C Pro plasmid, and cultivated 24 hours in 37 ℃.Cell is collected, and with centrifugal 5 minutes of 3,000rpm with isolated cell and substratum.At 100 μ l lysis buffers (25mM Tris-phosphoric acid, pH 7.8,2mM DTT (dithiothreitol (DTT)), 2mM 1,2-diamino-cyclohexane N, N, N, N '-tetraacethyl, 10% glycerine, 1%

X-100) re-suspended cell in, then freeze thawing (3 times) is with complete lysing cell.Cell lysate centrifugal 1 minute with 10,000rpm.The gained supernatant liquor is carried out galactoside enzymatic determination and Bradford mensuration, so that transfection efficiency normalization method, promoter activity is measured by the luciferase activity analysis.The results are shown in Fig. 2 A.

As shown in Fig. 2 A, FVII promotor and OATP-C promotor are induced higher levels of luciferase expression in hepatic cell line Huh-7.

In the Huh-7 cell, the activity that FVII Δ promotor shows is 2.5 times (seeing Fig. 2 B) of FVII promotor.

In the Huh-7 cell, the expression efficiency that FVII Δ promotor shows is 1.4% of CMV promotor, in the clone of its hetero-organization outside deriving from hepatic tissue 0.07% of average out to CMV promoter expression efficient.Yet different from the CMV promotor, FVII Δ promotor is 20 times (seeing Fig. 2 C) of its hetero-organization to the specificity of hepatic tissue.This result demonstration, FVII Δ promotor improves the expression efficiency of target gene and liver tissue-specific is had no adverse effect, so it is applicable to the expression vector of selectively acting in hepatic tissue.At Fig. 2 C, (-) represents negative control (lacking promotor), and ICAM2 represents the promotor of intracellular adhesion molecule, and Tie2 represents the promotor of tyrosine kinase receptor, endothelium glycoprotein represents the promotor of endothelium glycoprotein, and HBcP represents the hepatitis B virus promotor.

＜step 2〉the separation enhanser

In order to separate the PAH enhanser, as＜step 1〉as described in carry out PCR, but use the primer sets (SEQ ID NO:7 and 8) of PAH enhanser.The PCR product is carried out purifying by gel extraction, and be inserted in the pCR2.1-TOPO plasmid vector.PAH enhanser with nucleotide sequence of SEQ ID NO:44 is identified by restriction map and sequential analysis.Described plasmid called after " pCR-PAHenh ".In addition, repeat above-mentioned steps, but use the primer sets (SEQ ID NO:9 and 10) of AMBP enhanser, to build the pCR-AMBPenh plasmid with AMBP enhanser (nucleotide sequence with SEQ ID NO:45).The schematic diagram of pCR-PAHenh and pCR-AMBPenh plasmid is shown in Fig. 3 A.

PAH is separated with the pCR-AMBPenh plasmid by digesting pCR-PAHenh with SpeI and XbaI with the AMBP enhanser, carry out purifying by gel extraction, and be inserted into＜step 1〉in prepared pmRL-FVII Δ Pro and the SpeI site of pmRL-OATP-C Pro carrier.PmRL-FVII Δ Pro and pmRL-OATP-C Pro difference called after " pmRL-PF " and " pmRL-PO " with the combination of PAH enhanser.PmRL-FVII Δ Pro and pmRL-OATP-C Pro difference called after " pmRL-AF " and " pmRL-AO " with the combination of AMBP enhanser.Use SpeI and XbaI to extract the PAH enhanser from pmRL-PF, and be inserted into the SpeI site of pmRL-AF and pmRL-AO.Carrier called after " pmRL-PAF " and " pmRL-PAO " of gained.The schematic diagram of pmRL-PF, pmRL-PO, pmRL-AF, pmRL-AO, pmRL-PAF and pmRL-PAO carrier is shown in Fig. 3 B.

According to above-mentioned steps, insert to the upstream of OATP-C and FVII promotor and can strengthen in non-tissue-specific mode CMV and the SV40 enhanser of promoter activity.

＜step 3〉according to the expression efficiency of the combinatory analysis target gene of promotor and enhanser

＜3-1〉vitro test

Be in (being that the human pneumonocyte is (A549) and Human cervical cancer cell lines (HeLa)) in human liver cell system (Huh-7) and control cells, with＜step 1 in identical mode measure＜step 2 in the gene expression efficiency of constructed carrier.The results are shown in Fig. 4 A.

As shown in Fig. 4 A, with 28.4 times of specificity average out to other clones of carrier in hepatic cell line Huh-7 of PAH enhanser and FVII Δ promotor.This shows that the PAH enhanser makes the tissue specificity of FVII Δ promotor improve 1.42 times.The AMBP enhanser makes the tissue specificity of FVII Δ promotor improve 213.7 times or more, and this is approximately that the OATP-C promotor tissue specificity that caused by the AMBP enhanser improves (65.6 times) 3 times.The above results demonstration, enhanser can significantly improve the liver selectivity of FVII Δ promotor.

Controlling lower expression vector and control the activity of lower expression vector with respect to the CMV promotor in order to measure AMBP enhanser and FVII Δ promotor, is to have measured the expression level of luciferase in (being that kidney cell line (HEK293), lung cancer cell line (A549), cervical cancer tumer line (HeLa) and vascular endothelial cell are (HUVEC)) in human liver cell system (Huh-7, Hep3B) and control cells.The results are shown in Fig. 4 B.

As shown in Fig. 4 B, in hepatic cell line, contain luciferase expression efficient that the expression vector of AMBP enhanser and FVII Δ promotor shows and be 8.7% of the expression vector that contains the CMV promotor; In other clones, its average out to contain the CMV promotor expression vector luciferase expression efficient 0.14%.The liver tissue-specific that this demonstration contains the expression vector of AMBP enhanser and FVII Δ promotor is about 62 times high of its hetero-organization.

＜3-2〉the body build-in test

In order to measure the gene expression in vivo efficient in liver, injection＜step 2 in the mouse tail vein〉pmRL plasmid and polymine (PEI) (Polyplus, Illkirch, France) or body in jetPEI (Polyplus, Illkirch, France) every kind of mixture.Two days later, take out liver from described mouse, and measure the luciferase expression level.

Particularly, in 5% glucose solution with each and pcDNA-LacZ plasmid 10 μ g in pmRL-PO, pmRL-PF, pmRL-AO and the pmRL-AF plasmid of 40 μ g with PEI or body in the form of mixture of jetPEI be injected in mouse (six ages in week) tail vein.Two days later, liver, kidney, heart, spleen and lung tissue are separated from mouse, and carry out homogenate with homogenizer in PBS solution.Then, 500 μ l gained are organized solution and 500 μ l 2 * lysis buffers (50mM Tris-phosphoric acid, pH 7.8,4mM DTT (dithiothreitol (DTT)), 4mM 1,2-diamino-cyclohexane N, N, N, N '-tetraacethyl, 20% glycerine, 2%

X-100) mix, carry out thereafter freeze thawing (3 times) with complete lysing cell.Cell lysate centrifugal 1 minute with 10,000rpm.The gained supernatant carries out that galactoside enzymatic determination and Bradford measure so that transfection efficiency normalization method, and gene expression efficiency is measured by luciferase activity and measured.The results are shown in Fig. 4 C.

As shown in Fig. 4 C, in hepatic tissue, by contain luciferase expression level that the FVII Δ promotor/expression vector of PAH enhanser and the mixture of PEI induce equal by the CMV promotor induce 14%, this is 14 times of the luciferase expression external test or higher.The liver specificity luciferase expression level of being induced by FVII Δ promotor/AMBP enhanser equal by the CMV promotor induce 80%, this is 10 times of the luciferase expression external test or higher.

Replace PEI to improve the gene expression efficiency in the liver with jetPEI in body.Particularly, the liver specificity luciferase expression level of being induced by the mixture of jetPEI in the expression vector that contains OATP-C promotor/PAH enhanser and body equal by the CMV promotor induce approximately 38%, the luciferase expression level of being induced by FVII Δ promotor/PAH enhanser equal by the CMV promotor induce approximately 80%.The liver specificity luciferase expression level of being induced by the mixture of jetPEI in FVII Δ promotor/AMBP enhanser and body to induced by the CMV promotor similar.These results demonstrations, the activity of promotor of the present invention and enhanser is better than external in vivo.

Embodiment 2: separate the intron of hFIX UTR and liver specificity gene, and analyze the gene expression efficiency of UTR and intron

＜step 1〉identify the UTR of hFIX and build the expression vector that comprises UTR

Use RNA to extract test kit (Pharmacia Biotech) has extracted 1.2mg from the 1g human liver tissue total RNA, with homogenizer, described tissue is carried out homogenate in advance.Use uses DNA polymerase i (Takara) by the single stranded DNA synthetic double chain cDNA as the RNA that extracts, M-MuLV reversed transcriptive enzyme (Takara) and the synthesizing single-stranded DNA of oligo-dT17 primer (Takara) of template.

In order to assess FIX UTR to the impact of gene expression efficiency, use is carried out PCR as the cDNA of template, primer sets (SEQ ID NO:11 and 12) and the Ex-Taq that designs from FIX nucleotide sequence (Genbank accession number NM000133), to obtain to have the FIX cDNA of 5 ' UTR (SEQ ID NO:62) and 3 ' UTR (SEQ ID NO:63).The PCR condition is as follows: at first 94 ℃ of sex change are 5 minutes; 1 minute, 72 ℃ 30 circulations of extending 1 minute of 1 minute, 56 ℃ annealing of 94 ℃ of sex change; Last 72 ℃ were extended 3 minutes.

Except the primer sets of using SEQ ID NO:13 and 14, repeat above-mentioned steps, with the FIX cDNA that obtains not contain UTR in contrast.

The DNA fragmentation of amplification is digested with Restriction Enzyme NotI and SalI, carry out purifying by gel extraction, and be inserted into NotI and the SalI restriction site of pBluescript SK (+) carrier.The FIX that comprises the FIX of required UTR and do not contain UTR identifies by restriction map and sequential analysis.Described carrier is called after " pBS-hFIXUTR " and " pBS-hFIX " (seeing Fig. 5 (a)) respectively.

＜step 2〉separate the intron of liver specificity gene and build the expression vector that comprises intron

＜2-1〉structure pCR-int

At first, carry out PCR to obtain to comprise in people's antithrombin, proplasmin and thrombogen introne 1 the approximately fragment of 300bp of 5 ' end.

Particularly, use embodiment 1＜step 1〉described in genomic dna (as template) and the primer sets of people's antithrombin intron (SEQ ID NO:15 and 16), Human Plasminogen intron (SEQ ID NO:17 and 18) and human thrombin protoenzyme intron (SEQ ID NO:19 and 20) carry out under the following conditions PCR: at first 94 ℃ of sex change are 5 minutes; 1 minute, 72 ℃ 30 circulations of extending 2 minutes and 30 seconds of 1 minute, 60 ℃ annealing of 94 ℃ of sex change; Last 72 ℃ were extended 3 minutes.The PCR product is carried out purifying by gel extraction, and be inserted in the pCR2.1-TOPO carrier.SEQ ID NO:46,47 and 48 intron are identified by restriction map and sequential analysis.Described plasmid is called after " pCR-ATint ", " pCR-PLAint " and " pCR-PTint " respectively.

Further, the FIX introne 1 of reporting in order to separate Kurachi S repeats above-mentioned PCR step, but uses the primer sets (SEQ ID NO:21 and 22) of FIX introne 1, and the PCR product that obtains is inserted in the pCR2.1-TOPO carrier.The plasmid vector that produces digests with Restriction Enzyme PvuI or ScaI, and carries out from connecting.FIX intron with different sizes is identified by restriction map and sequential analysis.Described plasmid is called after " pCR-1.4kbFIXint " and " pCR-0.3kbFIXint " respectively.

＜2-2〉structure pBS-FIX-Syn 1int

Insertion＜2-1 between the

exons

1 and 2 of FIX〉in prepared pCR-ATint, pCR-PLAint and pCR-PTint intron fragment.

Particularly, repetition＜2-1〉PCR, but use the sense primer (SEQ ID NO:11) of FIX 5 ' UTR and the antisense primer (SEQ ID NO:23) of total donor splicing site sequence GTAA and triple G motif (deriving from the intron 2 of people's α-globin), to obtain to comprise the 5 ' UTR of FIX and the DNA fragmentation of exons 1, donor splicing site and the triple G motifs of people's α-globin.Further, repeat above-mentioned PCR, but the antisense primer (SEQ ID NO:12) of the sense primer of the branched sequence of end user's proplasmin and total splice acceptor sequence TCGA (SEQ ID NO:24) and FIX3 ' UTR is to obtain to comprise the DNA fragmentation of branched sequence, acceptor splicing site, exon 2 to 8 and FIX 3 ' UTR.The PCR product is carried out purifying by gel extraction, and be inserted in the pCR2.1-TOPO carrier.Required DNA fragmentation is identified by restriction map and sequential analysis.Described plasmid difference called after " pCR-5 ' hFIX " and " pCR-3 ' hFIX ".

PCR-5 ' hFIX and pCR-3 ' hFIX are digested with Restriction Enzyme NotI and NdeI and NdeI and SalI respectively, all be inserted into NotI and the SalI restriction site of pBluescript.The gained plasmid digests with NdeI, and insert with identical enzyme (NdeI) pretreated＜2-1 pCR-ATint, pCR-PLAint and pCR-PTint in.Required SEQ IDNO:49,50 and 51 introns are identified by restriction map and sequential analysis.Described plasmid is called after " pBS-hFIXUTR-Syn1AT " " pBS-hFIXUTR-Syn1PLA " and " pBS-hFIXUTR-Syn1PT " respectively.The schematic diagram of described plasmid is shown in Fig. 5 (b).

＜2-3〉structure pBS-FIX-Syn2int

General＜2-2〉the pBS-FIXUTR-Syn1PLA plasmid digest (for XhoI and the AatII restriction site adjacent with acceptor with donor splicing site) with XhoI and AatII, and insert with the pretreated＜2-1 of identical enzyme (XhoI and AatII) pCR-ATint, pCR-PLAint, pCR-PTint, pCR-1.4kbFIXint and pCR-0.3kbFIXint in.The intron of Syn2AT, Syn2PLA and Syn2PT (SEQ ID NO:52,53 and 54) and the intron of 1.4kbFIXint and 0.3kbFIXint are identified by restriction map.Described plasmid is called after " pBS-hFIXUTR-Syn2AT ", " pBS-hFIXUTR-Syn2PLA ", " pBS-hFIXUTR-Syn2PT ", " pBS-hFIXUTR-1.4kbFIXint (hFIXm1) " and " pBS-hFIXUTR-0.3kbFIXint (hFIXm2) " respectively.The schematic diagram of described plasmid is shown in Fig. 5 (c).

＜2-4〉separate antithrombin total length introne 1 and build the antithrombin intron that shortens

Repetition＜2-1〉PCR, but use the primer sets of SEQ ID NO:15 and 25, comprise the fragment of antithrombin total length introne 1 with amplification.The PCR product of about 2.3kb is inserted in the pCR2.1-TOPO carrier its called after " pCR-NAint ".The plasmid of gained digests with XhoI and AatII, and according to＜2-3〉step be inserted in pBS-hFIXUTR, to obtain to comprise the pBS-hFIXUTR-NA of SEQ ID NO:55 intron.

The intron that uses Kilo-Sequence Deletion Kit (Takara) to insert among pBS-hFIXUTR-NA from PvuII site brachymemma.Particularly, pBS-FIXUTR-NA is digested with PvuII, 25 ℃ of degradeds 15 seconds, 30 seconds, 45 seconds and 1 minute, carry out end-filling with mung-bean nuclease and klenow enzyme with exonuclease III, carry out at last from connecting.The construct of gained is transformed in intestinal bacteria.The transformant of gained is cultivated on the penbritin flat board and from wherein screening single bacterium colony, the size that derives from intron in the plasmid of described bacterium colony uses Restriction Enzyme to identify by electrophoresis.Plasmid with correct big or small intron is carried out purifying and order-checking, with the plasmid pBS-hFIXUTR-Δ NAL of the 811bp intron that obtains to comprise SEQ ID NO:56 and the plasmid pBS-hFIXUTR-Δ NAS that comprises the 640bp intron of SEQ ID NO:57.The schematic diagram of described plasmid pBS-hFIXUTR-NA, pBS-hFIXUTR-Δ NAL and pBS-hFIXUTR-Δ NAS is shown in Fig. 5 (d).

＜step 3〉analyze the impact that UTR and intron are expressed FIX

general＜step 1〉and＜step 2 in prepared pBS-hFIX, pBS-hFIXUTR, pBS-hFIXUTR-Syn1int (AT, PLA, PT) and pBS-hFIXUTR-Syn2int (AT, PLA, PT, 1.4kbFIXint, 0.3kbFIXint) plasmid digests with NotI and SalI, and be inserted in the pTRUF6 gland relevant viral vector that contains CMV promotor and ox poly (A), to obtain hFIX expression vector CMV-hFIX, CMV-hFIXUTR, CMV-hFIXUTR-Synlint (AT, PLA, PT) and CMV-hFIXUTR-Syn2int (AT, PLA, PT, 1.4kbFIXint, 0.3kbFIXint).

The plasmid DNA of the 25 above-mentioned expression vectors of μ g is expelled in the C57BL/6 mouse tail vein.Second day is collected blood sample and is used for following ELISA.

The gained blood sample is diluted 100 times in HBS-BSA-EDTA-T20 damping fluid (0.1MHEPES-0.1M NaCl-1%BSA-10mM EDTA-0.1%Tween-20).The blood sample of dilution is joined in 96 orifice plates that have been coated with people FIX (hFIX) antibody (Affinity Biologicals), in incubated at room temperature 90 minutes, with the PBS-0.1%Tween-20 washing, and with two anti-hatching of peroxidase labelling.Flat board is washed with PBS-0.1%Tween-20 again, and add wherein and be dissolved with O-phenylenediamine and H ₂O ₂Substrate buffer solution.Flat board is hatched 5 minutes, and use 2.5M H ₂SO ₄Termination reaction.Measure absorbancy with spectrophotometer (Spectra Shell Microplate Reader, STL Spectra, Milan, Italy) at 490nm, according to standard absorbance to the hFIX concentration in the typical curve calculation sample of normal concentration.The results are shown in Fig. 6 A.

As shown in Fig. 6 A, second day after injection, the haemoconcentration of the hFIX albumen of being induced by CMV-hFIXUTR is about 910ng/ml, is approximately 1.7 times by the CMV-hFIX institute's inducible protein (540ng/ml) that does not contain UTR.This shows that UTR helps the expression of hFIX.

The hFIX expression level (1 of CMV-hFIXUTR-Syn1PLA, 480ng/ml) height is to 1.6 times of CMV-hFIXUTR (910ng/ml), (2,170ng/ml) height is to 2.4 times of CMV-hFIXUTR (910ng/ml) for the hFIX expression level of CMV-hFIXUTR-Syn2AT.This shows that this intron participates in hFIX genetic expression and initial hFIX is protein induced.

Simultaneously, use expression vector CMV-hFIX, CMV-hFIXUTR and CMV-hFIXUTR-Syn1int (AT, PLA, PT) to produce recombinant adeno-associated virus rAAV-CMV-hFIX, rAAV-CMV-hFIXUTR and rAAV-CMV-hFIXUTR-Syn1int (AT, PLA, PT).Particularly, the HEK293T cell of preparation 200ml in the 500mlSpinner bottle is with low calcium DMEM substratum (0.1mM Ca ⁺⁺, 0.1%PL-68,1%FBS) described cell is adjusted to 1 * 10 ⁶The concentration of individual cell/ml.Be written into the DNA-PEI mixture of the 10 μ M PEI of the adenovirus helper plasmid pDG of each in the expression vector that comprises 33 μ g, 167 μ g and 650 μ l in the cell, and with described cell at 5%CO ₂In incubator with 30rpm suspension culture 6 hours.Then, substratum is replaced with the low calcium DMEM of 100 μ g T 500s.Cultivate after 48 hours, collecting cell carries out freeze thawing (3 times) and with 2000rpm centrifugal 5 minutes to it.The gained supernatant liquor carries out purifying (Zolotukhin, S. etc., Gene Ther., 6:973-985 (1999)) by Visipaque 320 gradient ultracentrifugation.With 1 * 10 ⁹Individual infectious particles (IP) is expelled in the tail vein of immunodeficiency type nude mice (Japan SLC Inc).After two weeks, collect weekly blood sample one time, and use it for ELISA as described above.The results are shown in Fig. 6 B.

As shown in Fig. 6 B, in 14 whens week after virus injection, the hFIX expression level that comprises the virus of intron of the present invention is 10 to 20 times of virus that do not contain intron.Particularly, be 19,996pg/ml with the hFIX protein concentration of the virus of CMV-hFIXUTR-Syn1AT, and be 2 with the hFIX protein concentration of the virus of CMV-hFIXUTR, 024pg/ml.This shows that intron of the present invention brings into play keying action aspect reinforcing gene expression.

＜step 4〉analyze intron to the impact of luciferase expression efficient and mRNA stability

＜4-1〉introduce intron in the luciferase expression carrier of being controlled by the TK promotor

PRL-TK expression vector (promega) is digested to remove the SV40 intron with HindIII/NheI, carry out thereafter end-filling and certainly connect.The pRL-TK carrier called after of intron brachymemma " pRL-Δ int " contains the pRL-TK carrier called after " pRL-SV40 " of SV40 intron.

General＜2-2〉and＜2-3 in pBS-hFIXUTR-Syn1AT, the pBS-hFIXUTR-Syn1PLA and the pBS-hFIXUTR-0.3kbFIXint that obtain digest and end-filling with XhoI/AatII.The gained fragment is inserted into above-mentioned expression vector pRL-Δ int.The gained carrier is called after " pRL-Syn1AT ", " pRL-Syn1PLA " and " pRL-hFIXm2 " (seeing Fig. 7 A) respectively.

＜4-2〉analysis luciferase expression efficient

As embodiment 1＜step 1〉described in, with 2 μ g＜4-1〉the mixture of luciferase expression carrier, 1 μ g beta-galactosidase enzymes expression vector and 6 μ g PEI (polyplus) be expelled in hepatic cell line (Hep3B), kidney cell line (HEK293) and pneumonocyte system (A549).After 48 hours, collecting cell and according to and embodiment 1＜step 1 in identical method measure luciferase expression efficient.The results are shown in Fig. 7 B.

As shown in Fig. 7 B, the luciferase expression of being induced by the expression vector that contains intron is up to 200 times that are induced by the expression vector that does not contain intron (situations that Syn1AT expresses in the Hep3B hepatic cell line).Especially, the Syn1AT expression vector obviously help inducing of luciferase activity and as＜step 3 described in inducing of expressing of FIX.

＜4-3〉analysis mrna expression stability

According to＜4-2 in identical method, general＜4-1〉the luciferase expression carrier be transfected in A549 pneumonocyte system, collecting cell after 48 hours.Use FastPure RNA test kit (Takara) to extract total RNA from described cell.Use every kind of total RNA of 500ng (as template) and AMV reversed transcriptive enzyme (Takara) preparation single stranded DNA.Then, use the primer sets of above-mentioned single stranded DNA (as template) and detection luciferase and beta-actin to carry out PCR.The results are shown in Fig. 8 A and 8B.

The RLuc mRNA relative quantity of being induced by the pRL-Syn1AT carrier as shown in Figure 8A and 8B, is 1.7 times of the RLuc mRNA that induced by pRL-Δ int.This shows, intron of the present invention has caused the more high stability of mRNA, and this higher stability causes the genetic expression that strengthens.

＜step 5〉analyze the antithrombin intron to the impact of FIX expression

In order to determine that the antithrombin intron is on the impact of hFIX protein expression, according to＜step 3 in identical method, general＜2-4〉in prepared pBS-hFIXUTR-NA, pBS-hFIXUTR-Δ NAL and pBS-hFIXUTR-NAS plasmid be inserted in the pTRUF6 adeno-associated virus, to obtain expression vector CMV-hFIXUTR-NA, CMV-hFIXUTR-Δ NAL and CMV-hFIXUTR-Δ NAS.According to＜step 3 in identical method, the plasmid DNA of expression vector CMV-hFIX, CMV-hFIXUTR, CMV-hFIXUTR-0.3kbFIXint (CMV-hFIXm2), CMV-hFIXUTR-Syn1AT, CMV-hFIXUTR-Syn2AT, CMV-hFIXUTR-Δ NA, CMV-hFIXUTR-Δ NAL and CMV-hFIXUTR-Δ NAS is expelled in mouse tail vein, and measures experimenter's blood hFIX concentration by ELISA.The results are shown in Fig. 9 A.

As shown in Fig. 9 A, the hFIX protein concentration that contains the expression vector of synthetic or natural antithrombin intron be 1.7 to 3.5 times of CMV-hFIXUTR (1,730 to 3,540ng/ml to 1,000ng/ml).Especially, the expression efficiency that shows of CMV-hFIXUTR-Δ NAL expression vector before being constructed CMV-hFIXm2 expression vector approximately 1.7 times (2,010ng/ml is to 1,000ng/ml).This shows that Δ NAL intron is very suitable for crossing of hFIX and expresses.

Simultaneously, in the impact of external assessment intron Δ NAL on the hFIX expression, expression vector CMV-hFIX, CMV-hFIXUTR and CMV-hFIXUTR-Δ NAL are transfected in the HEK293T kidney cell line.After transfection two days, collecting cell and substratum also carried out cracking.In lysate, the hFIX protein level is measured by the electrophoretic method that uses hFIX antibody, the results are shown in Fig. 9 B.

As shown in Fig. 9 B, the hFIX expression level that CMV-hFIXUTR-Δ NAL expression vector is induced is CMV-hFIX and CMV-hFIXUTR expression vector 1.55 times.This result shows that it is effectively that Δ NAL intron is crossed expression for hFIX.

Embodiment 3: separate liver specificity LCR and analyze the gene expression efficiency of LCR

＜step 1〉separate liver specificity LCR and build the plasmid vector that comprises LCR

The position of the downstream analysis TGTTTGC motif of the alpha1-antitrypsin in only being expressed in hepatic tissue, alpha-fetoprotein and albumin gene.The results are shown in Figure 10.

As shown in Figure 10, seven TGTTTGC motifs be distributed in the alpha1-antitrypsin gene-7.8kb, six motifs are forward, a motif is reverse; Also have the motif of a forward be positioned at the alpha1-antitrypsin gene-the 108bp site.In alpha-fetoprotein-3.8kb site, two TGTTTGC motifs distribute with forward, and a motif is reverse; Albumin gene-the 6kb site, a motif is reverse.In addition, the TGTTTGC motif in alpha1-antitrypsin gene-800bp site, a-fetoprotein gene-1.5kb and-500bp site and albumin gene-10kb ,-3.5kb and-the 2.6kb site clusters.In these sites, to alpha1-antitrypsin gene-7.8kb and-108bp site, a-fetoprotein gene-separate in 3.8kb site and albumin gene-6kb site.

Particularly, in order to separate the LCR that is positioned at alpha1-antitrypsin gene-1 08bp site, use embodiment 1＜step 1〉genomic dna (as template), SEQ ID NO:26 and 27 primer sets and archaeal dna polymerase (Ex-Taq, Takara) according to and embodiment 1＜step 1 in identical method carry out PCR.The PCR product is carried out purifying by gel extraction, and be inserted in the pCR2.1-TOPO carrier.The alpha1-antitrypsin LCR of the nucleotide sequence of the required SEQ of having ID NO:58 identifies by restriction map and sequential analysis.Described plasmid called after " pCR-AAT108lcr ".

Similarly, repeat above-mentioned PCR step, but use primer sets SEQ ID NO:28 and 29, SEQ ID NO:30 and 31 and SEQ ID NO:32 and 33, with amplification respectively be positioned at people's alpha1-antitrypsin-7.8kb site, human a-fetoprotein-3.8kb site and human albumin gene-LCR in 6kb site.The PCR product is inserted in the pCR2.1-TOPO carrier.The LCR of the required SEQ of having ID NO:59,60 and 61 nucleotide sequence identifies by restriction map and sequential analysis.Described plasmid is called after " pCR-AAT7800lcr ", " pCR-AFP3800lcr " and " pCR-E6lcr " respectively.

Simultaneously, in order to separate liver cell control region (HCR) and the minimal structure HCR (HCRm) of human apolipoprotein E (ApoE) gene that Dang Q. reports, use primer sets SEQ IDNO:34 and 35 and SEQ ID NO:34 and 36 carry out PCR, and the PCR product of gained is inserted in the pCR2.1-TOPO carrier.HCR and the HCRm of people ApoE gene identify by restriction map and sequential analysis.Described plasmid is called after " pCR-ApoEHCR " and " pCR-ApoEHCRm " respectively.The schematic diagram of these plasmids is shown in Figure 11 A.

Further, the combination of the enhanser of AAT gene and promotor and HCRm is inserted in pBluescript II carrier to build pBS-HCRm-AATenh/pro (HmA), the combination with HCR of the promotor of AAT gene is inserted in pBluescript II carrier with structure pBS-HCR-AATpro (HA).The schematic diagram of these plasmids is shown in Figure 11 B.

＜step 2〉analyze the gene expression efficiency of LCR

Right＜step 1〉in the LCR that separates and the combination of promotor, enhanser and intron, the impact of FIX expression efficiency is assessed.

Particularly, general＜step 1〉in prepared pCR-AAT108lcr, pCR-AAT7800cr, pCR-AFP3800lcr, pCR-E6lcr, pCR-HCR and pCR-HCRm plasmid digest with HindIII/EcoRV, and be inserted into embodiment 1＜step 2〉in HindIII/EcoRI (the filling after a while) restriction site of prepared pBS-PF, to obtain respectively pBS-AAT 108-PF, pBS-AAT7800-PF, pBS-AFP3800-PF, pBS-E6-PF, pBS-HCR-PF and pBS-HCRm-PF.These plasmids are digested again with KpnI and NotI, and be inserted into embodiment 2＜step 5〉in the KpnI/NotI restriction site of prepared pBS-CMV-hFIXUTR-Syn1PLA, to obtain pBS-AAT108-PF-hFIXUTR-Syn1PLA, pBS-AAT7800-PF-hFIXUTR-Syn1PLA, pBS-AFP3800-PF-hFIXUTR-Syn1PLA, pBS-E6-PF-hFIXUTR-Syn1PLA, pBS-HCR-PF-hFIXUTR-Syn1PLA and pBS-HCRm-PF-hFIXUTR-Syn1PLA.The schematic diagram of these plasmids is shown in Figure 12 A.

Described plasmid is digested with KpnI and SalI, and be inserted into the KpnI/SalI restriction site of pTRUF6 adeno-associated virus, to obtain expression vector AAT108-PF-hFIXUTR-Syn1PLA, AAT7800-PF-hFIXUTR-Syn1PLA, AFP3800-PF-hFIXUTR-Syn1PLA, E6-PF-hFIXUTR-Syn1PLA, HCR-PF-hFIXUTR-Syn1PLA and HCRm-PF-hFIXUTR-Syn1PLA.With the plasmid DNA of described expression vector according to and embodiment 2＜step 3 in same procedure be expelled in mouse tail vein, measure hFIX protein expression level by ELISA.The results are shown in Figure 12 B.

As shown in Figure 12B, injection two days later, (AAT7800-PF-hFIXUTR-Syn1PLA7,640ng/ml is to CMV-hFIXUTR-Syn1PLA 1,090ng/ml) up to 7 times of CMV-hFIXUTR-Syn1PLA to comprise hFIX expression level that the expression vector of LCR shows.Especially, until 4 weeks after injection, AAT108-PF-hFIXUTR-Syn1PLA is continuous expression 390ng/ml or higher hFIX still, and this expression level is up to 1.6 times of HCR-PF-FIX-Syn1PLA (250ng/ml).This result shows that the AAT108 intron is very suitable for the continuous expression of hFIX.

Embodiment 4: assess expression vector of the present invention to the result for the treatment of of hemophilia B

According to embodiment 3＜step 2 in identical method, with embodiment 1＜step 2〉in prepared pBS-PAF construction of expression vector AAT108-PAF-hFIXUTR-Syn1PLA.Then, with embodiment 2＜2-4〉in constructed pBS-CMV-hFIXUTR-Δ NAL digest with NotI and SalI, and be inserted into embodiment 3＜step 2〉in constructed AAT108-PF-hFIXUTR-Syn1PLA and the NotI/SalI restriction site of AAT108-PAF-hFIXUTR-Syn1PLA, to obtain AAT108-PF-hFIXUTR-Δ NAL and AAT 108-PAF-hFIXUTR-Δ NAL.

Simultaneously, with embodiment 1＜step 1〉pCR-AAT enh/pro digest with SpeI (filling after a while end)/NotI, and be inserted into embodiment 3＜step 2〉the EcoRV/NotI restriction site of pCR-HCRm, to obtain pCR-HCRm-AATenh/pro expression vector (HmA).PCR-HCRm-AATenh/pro (HmA) expression vector is digested with KpnI and NotI, and be inserted into embodiment 2＜step 5〉in KpnI and the NotI restriction site of constructed CM V-hFIXUTR-Δ NAL, to obtain the HmA-hFIXUTR-NAL expression vector.

With embodiment 1＜step 1〉described in pCR-AAT enh/pro digest with BglII (filling after a while)/NotI, and be inserted into embodiment 3＜step 2〉described in the EcoRV/NotI restriction site of pCR-HCR, to obtain pBS-HCR-AATpro (HA) expression vector.PBS-HCR-AATpro (HA) expression vector is digested with KpnI/NotI, and be inserted into embodiment 2＜step 3〉described in the KpnI/NotI restriction site of CMV-hFIXUTR-1.4kbFIXint, to obtain the HA-hFIXUTR-1.4kbFIXint expression vector.

The schematic diagram of described expression vector is shown in Figure 13 A.

Each plasmid DNA of AAT108-PF-hFIXUTR-Δ NAL, AAT108-PAF-hFIXUTR-Δ NAL, HmA-hFIXUTR-Δ NAL and the CMV-hFIXUTR-Δ NAL of 25 μ g (embodiment 2＜step 5〉in prepared) expression vector is expelled in the tail vein of hemophilia B mouse, and measures hFIX protein concentration and blood coagulation activity by ELISA.

As shown in Figure 13 B, with respect to the hFIX expression level of being induced by HmA-hFIXUTR-Δ NAL expression vector, the hFIX expression level of being induced by AAT108-PAF-hFIXUTR-Δ NAL expression vector after injection the 1st day be 9.8%, the 2nd day be 30.6%, the 7th day be 82%, the 2nd week was that 108%, the 9 week was 208%.In addition, with respect to the hFIX expression level of being induced by HmA-hFIXUTR-Δ NAL expression vector, the hFIX expression level of being induced by AAT108-PF-hFIXUTR-Δ NAL expression vector after injection the 1st day be 9%, the 2nd day is 19.2%, the 7th day is 41.9%, the 2nd week was that 56.9%, the 9 week was 73.0%.

Measure by following activated partial thromboplastin time (APTT) method with the hemophilia B mouse of hFIX expression vector injection and the blood coagulation activity of normal mouse.The mice plasma of FIX defective type blood plasma, 10 times of dilutions, the Actin muscle of activation (each 50 μ l) are mixed mutually, and hatched 3 minutes at 37 ℃.Add wherein CaCl ₂, the time of condensing and consuming with blood aggegation detector KC10A (Amelung) working sample.The clotting time of normal mouse is about 44 seconds, and the hemophilia B mouse is about 65 seconds.As shown in Figure 13 C, until injected rear 3 days, the hemophilia B mouse of having used the hFIX expression vector just demonstrates approximately 80% of the normal clotting time.After 7 days, the clotting time of having used the mouse of CMV-hFIXUTR-Δ NAL is returned to the level before injection, and the mouse of having used AAT108-PF-hFIXUTR-Δ NAL and AAT108-PAF-hFIXUTR-Δ NAL shows the clotting time and is improved as 50 to 60 seconds.

Further, according to standard activity, the typical curve in standard clotting time is calculated the blood coagulation activity of described sample.As shown in Figure 13 D, the hemophilia B mouse of processing with AAT108-PF-hFIXUTR-Δ NAL and AAT108-PAF-hFIXUTR-Δ NAL expression vector blood coagulation activity 8 weeks after injection be respectively 34.1% and 29.3% of normal mouse.Blood coagulation activity 8 weeks after injection of the mouse of processing with AAT108-PAF-hFIXUTR-Δ NAL expression vector especially, are 31.9% of normal mouse.

Simultaneously, according to embodiment 2＜step 3 in identical method, will use 2 * 10 of HA-hFIXUTR-1.4kbFIXint, AAT 108-PF-hFIXUTR-Δ NAL, AAT108-PAF-hFIXUTR-Δ NAL and CMV-hFIXUTR-1.4kbFIXint ⁹The recombinant adeno-associated virus of IP is expelled in the portal vein of hemophilia B mouse, and measures hFIX protein concentration and blood coagulation activity by foregoing ELISA and APTT method.The results are shown in Figure 14 A and 14B.

As shown in Figure 14 A, with the virus induction of the AAT108-PF-hFIXUTR-Δ NAL hFIX albumen up to 2,379ng/ml, with the virus induction of the AAT 108-PAF-hFIXUTR-Δ NAL hFIX albumen up to Isosorbide-5-Nitrae 31ng/ml.On the other hand, contrast virus (that is, with the virus of CMV-hFIXUTR-1.4kbFIXint with the virus of HA-hFIXUTR-1.4kbFIXint) the hFIX expression level of inducing is respectively 1,542ng/ml and 380ng/ml.Especially, the virus that contains AAT108-PF-hFIXUTR-Δ NAL also induced 500ng/ml or higher hFIX to express in 68 weeks after injection.This result shows, the expression vector that the present invention contains LCR is applicable to the gene therapy of the long-term genetic expression of needs.

As shown in Figure 14 B, used showed in 7 weeks after the injection with the mouse of the rAAV of AAT108-PF-hFIXUTR-Δ NAL the normal mouse blood coagulation activity 59.1% or higher.

The above results shows, gene expression system of the present invention is for required stable of Treatment of Hemophilia and expression that continue is effective.

Embodiment 5: structure comprises the liver specificity expression vector of anti-angiogenic generation albumin A po (a) kringle structural domain KIV9-KIV10-KV (LK68) gene and assesses LK68 protein expression efficient

In order to introduce Δ NAL intron and FIX UTR in the LK68 expression vector, at first use pAAV-LK68 (patent No. KR10-0681762), primer sets SEQ IDNO:37 and 38 as template, SEQ ID NO:39 and 40 and Ex-Taq carry out PCR, to obtain FIX 5 ' UTR signal sequence fragment and LK68-FIX 3 ' UTR fragment.The PCR condition is as follows: at first 94 ℃ of sex change are 5 minutes; 1 minute, 72 ℃ 30 circulations of extending 1 minute of 1 minute, 60 ℃ annealing of 94 ℃ of sex change; 72 ℃ of last extensions 3 minutes.Described 5 ' UTR signal sequence fragment and LK68-3 ' UTR fragment are inserted into respectively embodiment 2＜2-4〉in NotI/XhoI and the AatII/SalI restriction site of prepared pBS-hFIXUTR-Δ NAL carrier.Required DNA fragmentation is identified by restriction map and sequential analysis, described plasmid called after " pBS-LK68-Δ NAL-FUTR ".Will be by process the NotI/SalI restriction site that the resulting LK68-Δ of pBS-LK68-Δ NAL-FUTR plasmid NAL-FUTR fragment is inserted into AAT108-PF-hFIXUTR-NAL prepared in embodiment 4 with Restriction Enzyme NotI and SalI, to obtain expression vector AAT108-PF-LK68-Δ NAL-FUTR.Repeat above-mentioned steps when having Different L CR or lacking LCR, to obtain expression vector E6-PF-LK68-Δ NAL-FUTR, AAT7800-PF-LK68-Δ NAL-FUTR, AFP3800-PF-LK68-Δ NAL-FUTR, HCRm-PF-LK68-Δ NAL-FUTR, HCR-PF-LK68-Δ NAL-FUTR and PF-LK68-Δ NAL-FUTR.The restriction enzyme mapping of described expression vector is shown in Figure 15 A.

According to embodiment 2＜step 3 in identical method, described expression vector is expelled in mouse tail vein.Collect blood sample from mouse, and measure LK68 protein expression level by ELISA.

As shown in Figure 16 A, in Different L CR, AAT108 demonstrates the highest gene expression efficiency.Especially, LK68 expression efficiency with respect to PF-LK68-Δ NAL-FUTR expression vector, the LK68 expression efficiency of AAT108-PF-LK68-Δ NAL-FUTR expression vector after injection the 1st day be 158.4%, the 2nd day is 104.8%, the 7th day is 155.8%, the 2nd week was to be that 162.7%, the 4 week was 144.1% in 160.2%, the 3 week.

Further, repeat above-mentioned steps to obtain to comprise the expression vector of expression cassette AAT108-PF-LK68, AAT108-PF-LK68-FUTR, AAT108-PF-LK68-Δ NAL-FUTR, AAT108-PAF-LK68, AAT108-PAF-LK68-FUTR and AAT108-PAF-LK68-Δ NAL-FUTR.The schematic diagram of described expression vector is shown in Figure 15 B.

As shown in Figure 16 B, LK68 expression efficiency with respect to the AAT108-PF-LK68 expression vector, the LK68 expression efficiency of AAT108-PF-LK68-FUTR and AAT108-PF-LK68-Δ NAL-FUTR expression vector respectively after injection the 1st day be 197.7% and 425.4%, the 2nd day is 478.6% and 891.2%, the 7th day is 233.2% and 319.3%, the 2nd week was to be that 113.8% and 243.3%, the 4 week was 170.4% and 277.6% in 203.0% and 253.7%, the 3 week.LK68 expression efficiency with respect to the AAT108-PAF-LK68 expression vector, the LK68 expression efficiency of AAT 108-PAF-LK68-FUTR and AAT108-PAF-LK68-Δ NAL-FUTR expression vector respectively after injection the 1st day be 147.0% and 344.6%, the 2nd day is 351.0% and 824.5%, the 7th day is 220.2% and 260.3%, the 2nd week was 140.8% and 203.0%, the 3rd week was that 146.5% and 288.4%, the 4 week was 177.8% and 323.8%.

These results show, compare with the situation that does not have intron and UTR, and genetic expression is lasting high-caliber under intron and/or UTR existence.

Embodiment 6: the expression efficiency of anti-angiogenic generation albumin A po (a) the kringle structural domain KIV9-KIV10-KV (LK68) that is caused by UTR and intron in the assessment cell

To be inserted into adenovirus shuttle vector pENTR2B (Invitrogen by digesting the described AAT108-PF-LK68 of embodiment 5 and the resulting LK68 of AAT108-PF-LK68-Δ NAL-FUTR carrier and LK68-Δ NAL-FUTR fragment with NotI and SalI, Carlsbad, CA) in, to obtain pENTR-LK68 and pENTR-LK68-Δ NAL-FUTR carrier.These shuttle vectorss and target carrier pAd/CMV/V5-DEST (Invitrogen, Carlsbad, CA) are used Clonase ^TM(Invitrogen, Carlsbad, CA) carries out external homologous recombination, to obtain pAd-CMV-LK68 and pAd-CMV-LK68-Δ NAL-FUTR carrier.Described pAd-CMV-LK68 and pAd-CMV-LK68-Δ NAL-FUTR carrier are carried out linearizing with the PacI Restriction Enzyme, and be transfected in HEK 293 kidney cell lines, to obtain respectively replication-defective adenoviral rAd-LK68 and the rAd-LK68UN with CMV-LK68 and CMV-LK68-Δ NAL-FUTR.Described rAd-LK68 and rAd-LK68UN are expelled in HEK 293 kidney cell lines, and measure LK68 protein expression level.

Multi-infection plural number (MOI) with 0.1,0.5,2 and 10 infects HEK 293 kidney cell lines.2 days collecting cells and substratum after adenovirus infection.Use anti-LK68 antibody, by cataphoretic determination LK68 protein expression level.The results are shown in Figure 17 A and 17B.

As shown in Figure 17 A and 17B, when MOI is 0.1,0.5 and 2, LK68 protein expression level is very low and equal, yet when MOI is 10, with comparing of being induced by rAd-LK68, the LK68 protein expression level of being induced by rAd-LK68UN has improved 420% in cell, improved 242% in substratum.

These results show, UTR and intron exist gene expression efficiency in lower cell and substratum all higher than the situation that lacks UTR and intron.

Although invention has been described by above-mentioned specific embodiments, should be appreciated that and to carry out multiple modification and change, and still belong to by the defined scope of the invention of following claims.

Following content is corresponding to the original rights claim in female case application, and the existing part of book is as an illustration incorporated into herein:

Item 1. has the polynucleotide of the nucleotide sequence of SEQ ID NO:42.

Item 2. polynucleotide, it comprises the polynucleotide of the nucleotide sequence with SEQ ID NO:42; And at least one polynucleotide that Nucleotide effectively is connected more than described SEQ ID NO:42, the latter is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:44 and 45.

Item 3. polynucleotide, it is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:46 to 57.

Item 4. polynucleotide, it is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:58 to 61.

5. expression vectors, it comprises transcriptional regulatory element and effectively is connected and is subjected to the encoding sequence of its control with described transcriptional regulatory element, and wherein said transcriptional regulatory element comprises:

1) have the polynucleotide of the nucleotide sequence of SEQ ID NO:42;

2) have the polynucleotide of the nucleotide sequence of SEQ ID NO:42, and at least one polynucleotide that Nucleotide effectively is connected more than described SEQID NO:42, the latter is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:44 and 45;

3) have the polynucleotide of the nucleotide sequence of SEQ ID NO:42, and at least one polynucleotide that Nucleotide effectively is connected more than described SEQID NO:42, the latter is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:46 to 57;

4) have the polynucleotide of the nucleotide sequence of SEQ ID NO:42, and at least one polynucleotide that Nucleotide effectively is connected more than described SEQID NO:42, the latter is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:58 to 61;

5) have the polynucleotide of the nucleotide sequence of SEQ ID NO:42, be selected from least one polynucleotide of the polynucleotide of the nucleotide sequence with SEQID NO:44 and 45, and at least one polynucleotide that is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:46 to 57, described polynucleotide effectively connect each other;

6) have the polynucleotide of the nucleotide sequence of SEQ ID NO:42, be selected from least one polynucleotide of the polynucleotide of the nucleotide sequence with SEQID NO:44 and 45, and at least one polynucleotide that is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:58 to 61, described polynucleotide effectively connect each other;

7) have the polynucleotide of the nucleotide sequence of SEQ ID NO:42, be selected from least one polynucleotide of the polynucleotide of the nucleotide sequence with SEQID NO:46 to 57, and at least one polynucleotide that is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:58 to 61, described polynucleotide effectively connect each other; Perhaps

8) have the polynucleotide of the nucleotide sequence of SEQ ID NO:42, be selected from least one polynucleotide of the polynucleotide of the nucleotide sequence with SEQID NO:44 and 45, be selected from least one polynucleotide of the polynucleotide of the nucleotide sequence with SEQ ID NO:46 to 57; And at least one polynucleotide that is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:58 to 61, described polynucleotide effectively connect each other.

Item 6. expression vectors, it comprises transcriptional regulatory element and effectively is connected and is subjected to the encoding sequence of its control with described transcriptional regulatory element, described transcriptional regulatory element comprises promotor and the polynucleotide that effectively are connected with described promotor, and described polynucleotide are selected from: at least one polynucleotide that is selected from the polynucleotide of the nucleotide sequence with SEQ ID NO:46 to 57; Be selected from least one polynucleotide of the polynucleotide of the nucleotide sequence with SEQID NO:58 to 61; And have at least one polynucleotide of SEQ ID NO:46 Nucleotide more than 57 nucleotide sequences with being selected from of being selected from that at least one polynucleotide with SEQ ID NO:58 Nucleotide more than 61 nucleotide sequences effectively are connected.

The expression vector that item is 7. 5 or 6, wherein said encoding sequence is the sequence of coding liver-specific protein matter, and described protein is selected from: albumin, alpha-fetoprotein, alpha-glucosidase, alpha1-antitrypsin, antithrombin, lipoprotein, ceruloplasmin, proconvertin, blood coagulation factor VIII, plasma thromboplastin component, erythropoietin, Fibrinogen, glucocerebrosidase, haptoglobin, IGF-1, Regular Insulin, proplasmin, thrombogen and Transferrins,iron complexes.

The expression vector of 8. 5 or 6, it also comprises and lays respectively at described encoding sequence 5 ' and the polynucleotide of the nucleotide sequence with SEQ ID NO:62 and 63 of 3 ' end.

Claims

1. polynucleotide, its nucleotides sequence is classified nucleotide sequence shown in SEQ ID NO:49 as.

2. expression cassette, it comprises:

Promotor;

Effectively be connected and be subjected to the encoding sequence of its control with described promotor; With

With the intron that described encoding sequence effectively is connected, its nucleotides sequence is classified nucleotide sequence shown in SEQ ID NO:49 as.

3. the expression cassette of claim 2, it also contains at least one enhanser that effectively is connected with described encoding sequence, and its nucleotide sequence is selected from nucleotide sequence shown in SEQ ID NO:44 and 45.

4. the expression cassette of claim 2, it also contains at least one region that effectively is connected with described encoding sequence, and its nucleotide sequence is selected from nucleotide sequence shown in SEQ ID NO:58 to 61.

5. the expression cassette of claim 2, it also contains the non-translational region that effectively is connected with described encoding sequence, its nucleotides sequence classify as respectively 5 of described encoding sequence ' and the SEQ ID NO:62 and 63 of 3 ' end shown in nucleotide sequence.

6. the expression cassette of claim 3, it also contains at least one region that effectively is connected with described encoding sequence, and its nucleotide sequence is selected from nucleotide sequence shown in SEQ ID NO:58 to 61.

7. the expression cassette of claim 6, it also contains the non-translational region that effectively is connected with described encoding sequence, its nucleotides sequence classify as respectively 5 of described encoding sequence ' and the SEQ ID NO:62 and 63 of 3 ' end shown in nucleotide sequence.

8. the expression cassette of claim 3, it also contains the non-translational region that effectively is connected with described encoding sequence, its nucleotides sequence classify as respectively 5 of described encoding sequence ' and the SEQ ID NO:62 and 63 of 3 ' end shown in nucleotide sequence.

9. the expression cassette of claim 4, it also contains the non-translational region that effectively is connected with described encoding sequence, its nucleotides sequence classify as respectively 5 of described encoding sequence ' and the SEQ ID NO:62 and 63 of 3 ' end shown in nucleotide sequence.

10. the expression cassette of any one in claim 2 to 9, wherein said promotor is selected from the polynucleotide that nucleotides sequence is classified nucleotide sequence shown in SEQ ID NO:41,42 and 43 as.

11. the expression cassette of any one in claim 2 to 9, wherein said encoding sequence is the nucleotide sequence of coded protein, and described protein is selected from: albumin, alpha-fetoprotein, alpha-glucosidase, alpha1-antitrypsin, antithrombin, lipoprotein, ceruloplasmin, proconvertin, blood coagulation factor VIII, plasma thromboplastin component, erythropoietin, Fibrinogen, glucocerebrosidase, haptoglobin, IGF-1, Regular Insulin, proplasmin, thrombogen and Transferrins,iron complexes.

12. expression vector, it contains the expression cassette of any one in claim 2 to 9.